Abstract
BackgroundOral cladribine (OC) is approved for the treatment of highly active relapsing multiple sclerosis. Postmarketing safety assessments have reported rare, but occasionally severe cases of liver injury in temporal association with OC, with pathophysiologic mechanisms still unknown. In the only detailed case report on this topic, idiosyncratic drug-induced liver injury (iDILI) during OC treatment was well characterised for the first time, but occurred in the context of prior high-dose steroid exposure. Although high-dose steroids are known to induce iDILI in patients with multiple sclerosis with a delay of up to 12 weeks, OC was assumed to be the culprit agent for observed liver injury and the role of steroid exposure was not further investigated.CaseHerein, we describe a case of a 35-year-old women treated with high-dose oral prednisolone during the first treatment cycle OC and subsequently developed iDILI. A causality assessment of the role of prednisolone and OC was performed using the updated Roussel Uclaf Causality Assessment Method which also included a negative re-exposure test for OC during the second OC treatment cycle 1 year later.ConclusionOur observations suggest that prednisolone or interactions between prednisolone and OC are more likely to foster development of iDILI rather than OC treatment itself.
Subject
Neurology (clinical),Neurology
Reference13 articles.
1. European Medicines Agency . Mavenclad (Cladribine) – risk of serious liver injury and new recommendations about liver function monitoring. 2022. Available: https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-mavenclad-cladribine-risk-serious-liver-injury-new_en.pdf
2. Updated post-approval safety of cladribine tablets in the treatment of multiple sclerosis, with particular reference to liver safety;Giovannoni;Mult Scler,2022
3. Acute idiosyncratic liver injury after cladribine treatment for multiple sclerosis: first case report and review on associated hepatic disorders;Saraceno;Mult Scler,2022
4. The disease-modifying therapies of relapsing-remitting multiple sclerosis and liver injury: a narrative review;Biolato;CNS Drugs,2021
5. Cladribine-induced liver injury: implications for practice;Brownlee;Mult Scler,2022
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Multiple drugs;Reactions Weekly;2023-10-14